Compare ZTO & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTO | VANI |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 119.0M |
| IPO Year | 2016 | 2014 |
| Metric | ZTO | VANI |
|---|---|---|
| Price | $20.58 | $1.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $23.65 | $3.50 |
| AVG Volume (30 Days) | ★ 1.7M | 231.2K |
| Earning Date | 05-19-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | $14.01 | N/A |
| Revenue Next Year | $9.12 | N/A |
| P/E Ratio | $21.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.11 | $0.92 |
| 52 Week High | $26.20 | $1.92 |
| Indicator | ZTO | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 28.57 | 40.80 |
| Support Level | N/A | $1.26 |
| Resistance Level | $22.84 | $1.55 |
| Average True Range (ATR) | 0.33 | 0.08 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 29.30 | 3.74 |
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 20.1% in 2026. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and a major shareholder with 78.7% voting rights as of March 31, 2026. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around a 9.3% interest.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.